Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer

Wang, 2017, TP53 mutations, expression and interaction networks in human cancers, Oncotarget, 8, 624, 10.18632/oncotarget.13483

Munoz-Fontela, 2016, Emerging roles of p53 and other tumour-suppressor genes in immune regulation, Nat Rev Immunol, 16, 741, 10.1038/nri.2016.99

Zitvogel, 2015, CANCER. A p53-regulated immune checkpoint relevant to cancer, Science, 349, 476, 10.1126/science.aac8475

Textor, 2011, Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2, Cancer Res, 71, 5998, 10.1158/0008-5472.CAN-10-3211

Shatz, 2012, The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells, Cancer Res, 72, 3948, 10.1158/0008-5472.CAN-11-4134

Guo, 2017, Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity, Cancer Res, 77, 2292, 10.1158/0008-5472.CAN-16-2832

Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer cell, 27, 450, 10.1016/j.ccell.2015.03.001

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711

Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498

Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Hugo, 2016, Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065

Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095

Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, 20, 5064, 10.1158/1078-0432.CCR-13-3271

Le, 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Bernstein, 2017

Ye, 2016, Genomic alterations and molecular subtypes of gastric cancers in Asians, Chin J Cancer, 35, 42, 10.1186/s40880-016-0106-2

Chen, 2015, The updated incidences and mortalities of major cancers in China, 2011, Chin J Cancer, 34, 502

Cancer Genome Atlas Research, N, 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480

Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat Med, 21, 449, 10.1038/nm.3850

Chen, 2016, Emerging molecular classifications and therapeutic implications for gastric cancer, Chin J Cancer, 35, 49, 10.1186/s40880-016-0111-5

Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460

Hanzelmann, 2013, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinformatics, 14, 7, 10.1186/1471-2105-14-7

Benjami, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc B, 57, 289, 10.1111/j.2517-6161.1995.tb02031.x

Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, 102, 15545, 10.1073/pnas.0506580102

Yoshihara, 2013, Inferring tumour purity and stromal and immune cell admixture from expression data, Nat Commun, 4, 2612, 10.1038/ncomms3612

Kanehisa, 2017, KEGG: new perspectives on genomes, pathways, diseases and drugs, Nucleic Acids Res, 45, D353, 10.1093/nar/gkw1092

Kim, 2015, ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients, Commun Stat Appl Methods, 22, 665

Rooney, 2015, Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell, 160, 48, 10.1016/j.cell.2014.12.033

Vinay, 2015, Immune evasion in cancer: Mechanistic basis and therapeutic strategies, Semin Cancer Biol, 35, S185, 10.1016/j.semcancer.2015.03.004

Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967

Lee, 2015, Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes, Breast Cancer Res Treat, 151, 619, 10.1007/s10549-015-3438-8

Massink, 2015, Genomic profiling of CHEK2*1100delC-mutated breast carcinomas, BMC Cancer, 15, 877, 10.1186/s12885-015-1880-y

Tanaka, 2017, Regulatory T cells in cancer immunotherapy, Cell Res, 27, 109, 10.1038/cr.2016.151

De Simone, 2016, Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells, Immunity, 45, 1135, 10.1016/j.immuni.2016.10.021

Lippitz, 2013, Cytokine patterns in patients with cancer: a systematic review, Lancet Oncol, 14, e218, 10.1016/S1470-2045(12)70582-X

Wong, 2016, Characterization of cytokinome landscape for clinical responses in human cancers, Oncoimmunology, 5, 10.1080/2162402X.2016.1214789

Caballero, 2009, Cancer/testis (CT) antigens: potential targets for immunotherapy, Cancer Sci, 100, 2014, 10.1111/j.1349-7006.2009.01303.x

Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res, 37, D816, 10.1093/nar/gkn673

Renaud, 2007, Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors, Nucleic Acids Res, 35, 7372, 10.1093/nar/gkm896

Munro, 1976, Products of the major histocompatibility complex and their relationship to the immune response, Nature, 264, 145, 10.1038/264145a0

Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat Commun, 4, 2359, 10.1038/ncomms3359

Fritsch, 2014, Personal neoantigen cancer vaccines: The momentum builds, Oncoimmunology, 3, 10.4161/onci.29311

Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025

Bedognetti, 2015, Prognostic and predictive immune gene signatures in breast cancer, Curr Opin Oncol, 27, 433, 10.1097/CCO.0000000000000234

Aran, 2016, Widespread parainflammation in human cancer, Genome Biol, 17, 145, 10.1186/s13059-016-0995-z

Kastenhuber, 2017, Putting p53 in Context, Cell, 170, 1062, 10.1016/j.cell.2017.08.028

Bakhoum, 2018, Chromosomal instability drives metastasis through a cytosolic DNA response, Nature, 553, 467, 10.1038/nature25432

Chen, 2016, The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression, Cold Spring Harb Perspect Med, 6, a026104, 10.1101/cshperspect.a026104

Wang, 2017, TP53 mutations, expression and interaction networks in human cancers, Oncotarget, 8, 624, 10.18632/oncotarget.13483

Goel, 2017, CDK4/6 inhibition triggers anti-tumour immunity, Nature, 548, 471, 10.1038/nature23465

Kawamura, 2004, Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression, Cancer Res, 64, 4800, 10.1158/0008-5472.CAN-03-3908

Floter, 2017, Regulation of Metabolic Activity by p53, Metabolites, 7, 10.3390/metabo7020021

Smyth, 2016, Combination cancer immunotherapies tailored to the tumour microenvironment, Nat Rev Clin Oncol, 13, 143, 10.1038/nrclinonc.2015.209